Ved invasiv aspergillose var der ved behandlingens afslutning positiv reaktion hos 42% af de patienter, der fik Posaconazole SP, mod 26% i sammenligningsgruppen.
In invasive aspergillosis, a successful response at the end of treatment was seen in 42% of the patients taking Posaconazole SP, compared with 26% of the comparison group.